ESPR
Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$2.00
+4.71% today
Updated 2026-04-30
Market cap
$491.64M
P/E ratio
—
P/S ratio
1.22x
EPS (TTM)
$-0.11
Dividend yield
—
52W range
$1 – $4
Volume
6.1M
Esperion Therapeutics Inc (ESPR) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-1.6%
Last 4 quarters
Revenue YoY growth
+143.7%
Most recent quarter
EPS YoY growth
+317.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.9%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-9.5%
2025-11-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-24 | $0.22 | -24.6% | $3.34 | $3.33 | -0.3% |
| 2025-11-06 | $-0.16 | -900.0% | $2.94 | $2.66 | -9.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.29 | $0.22 | -24.6% | $168.45M | +143.7% |
| 2025-09-30 | $0.02 | $-0.16 | -900.0% | $87.31M | +69.1% |
| 2025-06-30 | $-0.14 | $-0.06 | +57.1% | $82.39M | +11.6% |
| 2025-03-31 | $-0.15 | $-0.21 | -37.5% | $65.00M | -52.8% |
| 2024-12-31 | $-0.16 | $-0.10 | +35.7% | $69.11M | +114.3% |
| 2024-09-30 | $-0.18 | $-0.15 | +16.7% | $51.63M | +52.0% |
| 2024-06-30 | $-0.18 | $-0.33 | -83.3% | $73.83M | +186.3% |
| 2024-03-31 | $0.05 | $0.34 | +580.0% | $137.74M | +466.1% |
| 2023-12-31 | $-0.48 | $-0.50 | -4.2% | $32.25M | — |
| 2023-09-30 | $-0.43 | $-0.37 | +14.0% | $33.97M | — |
| 2023-06-30 | $-0.61 | $-0.46 | +24.6% | $25.79M | — |
| 2023-03-31 | $-0.65 | $-0.79 | -21.5% | $24.33M | — |
Frequently asked questions
Has Esperion Therapeutics Inc beaten earnings estimates?
Esperion Therapeutics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -1.6% over the last 3 quarters.
How does ESPR stock react to earnings?
ESPR stock has moved an average of -4.9% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Esperion Therapeutics Inc's revenue growth rate?
Esperion Therapeutics Inc reported year-over-year revenue growth of +143.7% in its most recent quarter, with EPS growing +317.2% year-over-year.